EP0946524A1 - Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endotheline - Google Patents
Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endothelineInfo
- Publication number
- EP0946524A1 EP0946524A1 EP97952876A EP97952876A EP0946524A1 EP 0946524 A1 EP0946524 A1 EP 0946524A1 EP 97952876 A EP97952876 A EP 97952876A EP 97952876 A EP97952876 A EP 97952876A EP 0946524 A1 EP0946524 A1 EP 0946524A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- nitrogen
- optionally substituted
- phenyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
- C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Definitions
- the present invention relates to new carboxylic acid derivatives, their preparation and use.
- Endothelin is a 21 amino acid peptide that is synthesized and released by vascular endothelium. Endothelin exists in three isoforms, ET-1, ET-2 and ET-3. In the following, "endothelin” or “ET” means one or all isoforms of endothelin. Endothelin is a potent vasoconstrictor and has a strong effect on vascular tone. This vasoconstriction is known to be caused by the binding of endothelin to its receptor (Nature, 332, 411-415, 1988; FEBS Letters, 211, 440-444, 1988 and Biochem. Biophys. Res. Commun., 15_4, 868-875, 1988).
- endothelin causes persistent vascular contraction in peripheral, renal, and cerebral blood vessels, which can lead to disease.
- endothelin is involved in a number of diseases. These include: hypertension, acute myocardial infarction, pulmonary hypertension, Raynaud's syndrome, cerebral vasospasm, stroke, benign prostatic hypertrophy, atherosclerosis and asthma (J. Vasicular Med. Biology 2, 207 (1990), J. Am. Med. Association 264 . 2868 (1990), Nature 114 (1990), N. Engl. J. Med. 322, 205 (1989), N. Engl. J. Med. 311, 1732 (1993), Nephron 66., 373
- ET A and ET B receptor are currently described in the literature (Nature 348, 730
- the task was to provide endothelin receptor antagonists that bind to the ET A and / or the ET B receptor.
- the invention relates to carboxylic acid derivatives of the formula I.
- R 1 stands for tetrazole or for a group
- Hydrogen the cation of an alkali metal, the cation of an alkaline earth metal, a physiologically compatible organic ammonium ion such as tertiary C 1 -C 4 -alkylammonium or the ammonium ion;
- R 6 may furthermore be a phenyl radical which one to five halogen atoms and / or can carry one to three of the following radicals: nitro, cyano, C 1 -C 4 -alkyl, C 4 haloalkyl, hydroxy, C ⁇ -C 4 -Alkoxy, mercapto, -CC 4 -alkylthio, amino, NH (C ⁇ -C alkyl), N (C1 . -C 4 alkyl) 2 ;
- a 5-membered hetero-aroat linked via a nitrogen atom such as pyrrolyl, pyrazolyl, imidazolyl and triazolyl, which has one or two halogen atoms, or one or two
- R 8 means:
- Y is nitrogen or CR 9 ;
- CR 9 or CR 10 forms together with CR 9 or CR 10 a 5- or 6-membered alkylene or alkenylene ring, which can be substituted by one or two C 1 -C 4 -alkyl groups, and in each case one or more methylene groups by oxygen, sulfur, -NH or -N (-CC 4 alkyl), can be replaced;
- R 3 and R 4 (which may be the same or different):
- Phenyl or naphthyl, which by one or more of the fol- constricting radicals may be substituted halogen, nitro, cyano, hydroxy, mercapto, C ⁇ -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl , C ⁇ -C4 haloalkyl, C ⁇ -C4-alkoxy, phenoxy, C ⁇ -C alkoxy-halo, C 1 -C 4 alkylthio, amino, NH (C 1 -C 4 alkyl), N (C ⁇ - C 4 alkyl) 2 or phenyl, which can be substituted one or more times, for example one to three times by halogen,
- Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an SO, NH or N-alkyl group;
- R 5 is hydrogen, Cx-Cs-alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 -alkynyl, where these radicals can each be substituted one or more times by: halogen, hydroxy, mercapto, carboxy, nitro, amino , cyano, C 1 -C 4 alkoxy, C 3 -C 6 alkenyloxy, C 3 -C 6 alkynyloxy, C ⁇ -C 4 alkylthio, C ⁇ -C -haloalkoxy, C ⁇ -C alkyl-carbonyl, C ⁇ -C 4 -Alkoxycarbonyl, C 3 -C 8 alkylcarbonylalkyl, NH (C ⁇ -C 4 ⁇ lkyl), N (C!
- aryl radicals mentioned can in turn be mono- or polysubstituted, for example one to three times by halogen, hydroxy, mercapto, carboxy, Nitro, cyano, C 1 -C 4 -alkyl, C ⁇ -C4-haloalkyl, C ⁇ -C 4 -alkoxy, C 4 haloalkoxy, amino, NH (C 1 -C 4 alkyl), N (C 1 -C 4 alkyl) 2 or C 1 -C 4 -alkylthi ⁇ ;
- Phenyl or naphthyl which in each case by one or more of the following radicals can be substituted halogen, nitro, cyano, hydroxy, amino, C ⁇ -C 4 alkyl, C 1 -C 4 haloalkyl, C ⁇ -C4-alkoxy, C ⁇ -C -haloalkoxy, phenoxy, -C-alkyl thio, -C-C 4 -alkylamino, -C-C 4 -dialkylamino, dioxomethylene or dioxoethylene;
- a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom which can carry one to four halogen atoms and / or one or two of the following radicals: C 1 -C 4 alkyl, -C-C 4 -Halogenalkyl, -C-C 4 alkoxy, -C-C 4 -haloalkoxy,
- C 1 -C 4 alkylthio P enyl, phenoxy or phenylcarbonyl, where the phenyl radicals or may carry one to three of the following radicals in turn one to five halogen atoms and / a: C 1 -C 4 -alkyl, C 4 haloalkyl, C; ⁇ _-C 4 -alkoxy, C 4 -haloalkoxy and / or C1.
- -C 4 alkylthio
- C 3 -C 8 -cycloalkyl where these radicals in each case may be mono- or polysubstituted by: halogen, hydroxy, mercapto, carboxy, nitro, cyano, C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C ⁇ -C 4 -alkoxy, C 4 alkylthio, C ⁇ -C4-halo-alkoxy;
- R 9 and R 10 (which may be the same as different):
- CR 9 or CR 10 is linked to CR 2 as stated under R 2 to form a 5- or 6-membered ring;
- An alkali metal is e.g. Lithium, sodium, potassium;
- alkaline earth metal is e.g. Calcium, magnesium, barium;
- Organic ammonium ions are protonated amines such as e.g. Ethanolamine, diethanolamine, ethylenediamine, diethylamine or piperazine;
- C 3 -C 8 cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
- C 1 -C 4 -Halogenalkyl can be linear or branched, such as fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2, 2, 2-trifluoroethyl, 2nd -Chlor-2, 2-difluoroethyl, 2, 2-dichloro-2-fluoroethyl, 2, 2, 2-trichloroethyl or pentafluoroethyl;
- C 1 -C 4 -Halogenalkoxy can be linear or branched such as difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2, 2-difluoroethoxy, 1, 1, 2, 2-tetrafluoroethoxy, 2,2,2-trifluoroethoxy , 2-chloro-l, 1, 2-trifluoroethoxy, 2-fluoroethoxy or pentafluoroethoxy;
- C 1 -C 4 -alkyl can be linear or branched, such as methyl, ethyl, 1-propyl, 2-propyl, 2-methyl-2-propyl, 2-methyl-1-propyl, 1-butyl or 2-butyl;
- C 2 -C 4 alkenyl can be linear or branched, such as, for example, ethenyl, l-propen-3-yl, l-propen-2-yl, 1-propen-l-yl, 2-methyl-l-propenyl, 1- Butenyl or 2-butenyl;
- C 2 -C 4 alkynyl can be linear or branched, such as, for example, ethynyl, 1-propyn-1-yl, 1-propyn-3-yl, 1-butyn-4-yl or 2-butyn-4-yl;
- C 1 -C 4 -alkoxy can be linear or branched such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1-dimethylethoxy;
- C 3 -C 6 alkenyloxy can be linear or branched, for example allyloxy, 2-buten-1-yloxy or 3-buten-2-yloxy;
- C 3 -C 6 alkynyloxy can be linear or branched, such as 2-propyn-1-yloxy, 2-butyn-1-yloxy or 3-butyn-2-yloxy;
- C ⁇ -C 4 ⁇ alkylthio can be linear or branched such as methyl thio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1, 1-dimethylethylthio;
- C 1 -C 4 -alkylcarbonyl can be linear or branched, such as acetyl, ethylcarbonyl or 2-propylcarbonyl;
- C 1 -C 4 -alkoxycarbonyl can be linear or branched such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, i-propoxycarbonyl or n-butoxycarbonyl;
- C 3-8 alkylcarbonylalkyl can be linear or branched, for example 2-oxo-prop-1-yl, 3-oxo-but-1-yl or 3-oxo-but-2-yl;
- C 1 -C 8 alkyl can be linear or branched, such as C 1 -C 4 alkyl, pentyl, hexyl, heptyl or octyl;
- C -C 8 alkenyl can be linear or branched, such as, for example, l-propen-3-yl, l-propen-2-yl, 1-propen-l-yl, 2-methyl-l-propenyl, l-buten-4 -yl, 2-buten-3-yl, l-penten-5-yl, l-hexen-6-yl, 3-hexen-6-yl, 2-hepten-7-yl or l-0cten-8 -yl;
- C 3 -C 8 alkynyl can be linear or branched, such as, for example, 1-propyn-1-yl, 1-propyn-3-yl, 1-butyn-4-yl, 2-butyn-4-yl, 2-pentyn 5-yl, 3-hexin-6-yl, 3-heptin-7-yl, 2-octin-8-yl;
- Halogen is e.g. Fluorine, chlorine, bromine, iodine.
- the invention further relates to those compounds from which the compounds of the formula I can be released (so-called prodrugs).
- prodrugs in which the release takes place under conditions such as those in certain body compartments, e.g. in the stomach, intestines, bloodstream, liver, predominate.
- the compounds I and also the intermediates for their preparation, such as II, III, IV and V, can have one or more asymmetrically substituted carbon atoms. Such compounds can exist as pure enantiomers or pure diastereomers or as a mixture thereof. The use of an enantiomerically pure compound as the active ingredient is preferred.
- the invention further relates to the use of the above-mentioned carboxylic acid derivatives for the production of medicaments, in particular for the production of inhibitors for ET A and / or ET B receptors.
- the compounds according to the invention are suitable as antagonists as defined at the outset.
- Compounds of general formula III are either known or can e.g. can be synthesized by reducing the corresponding carboxylic acids or their esters, or by other generally known methods.
- N Z VII In formula VII, R is halogen or R i2 -S0 2 -, where R 12
- the reaction preferably takes place in an inert solvent or diluent with the addition of a suitable base, ie a base which brings about a deprotonation of the intermediate IV, in a temperature range from room temperature to the boiling point of the solvent.
- a suitable base ie a base which brings about a deprotonation of the intermediate IV, in a temperature range from room temperature to the boiling point of the solvent.
- solvents or diluents are aliphatic, alicyclic and aromatic hydrocarbons, each of which may optionally be chlorinated, such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene, Ethers such as diisopropyl ether, dibutyl ether, methyl tert.
- chlorinated such as, for example, hexane, cyclohexane, petroleum ether, ligroin, benzene, toluene, xylene, methylene chloride, chloroform, carbon tetrachloride, ethyl chloride and trichlorethylene
- Ethers such as diisopropyl ether, dibutyl ether, methyl tert.
- nitriles such as, for example, acetonitrile and propionitrile
- acid amides such as, for example, dimethylformamide, dimethylacetamide and N-methylpyrrolidone
- sulfoxides and sulfones such as, for example, dimethyl sulfoxide and sulfolane.
- An alkali or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as alkali metal carbonate, for example sodium or potassium carbonate, an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide, can be used as the base.
- a carbonate such as alkali metal carbonate, for example sodium or potassium carbonate
- an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide
- an organometallic compound such as butyllithium or an alkali amide such as lithium diisopropylamide or lithium amide.
- Compounds of the formula I can also be prepared by starting from the corresponding carboxylic acids, ie compounds of the formula I in which R 1 is COOH, and converting them first in the usual manner into an activated form such as an acid halide, an anhydride or Imidazolid transferred and then reacted with a corresponding hydroxyl compound H ⁇ R 7 .
- This reaction can be carried out in the customary solvents and often requires the addition of a base, the above-mentioned being possible.
- These two steps can also be simplified, for example, by allowing the carboxylic acid to act on the hydroxyl compound in the presence of a water-releasing agent such as a carbodiide.
- compounds of the formula I can also be prepared by starting from the salts of the corresponding carboxylic acids, ie from compounds of the formula I in which R 1 is a group COR and R is OM, where M is an alkali metal cation or can be the equivalent of an alkaline earth metal cation.
- R 1 is a group COR and R is OM
- M is an alkali metal cation or can be the equivalent of an alkaline earth metal cation.
- These salts can be reacted with many compounds of the formula RA, where A is a customary nucleofugic leaving group, for example halogen such as chlorine, bromine, iodine or aryl- or alkylsulfonyl optionally substituted by halogen, alkyl or haloalkyl, such as toluenesulfonyl and methylsulfonyl or one other equivalent leaving group.
- A is a customary nucleofugic leaving group, for example hal
- carboxylic acid derivatives of the general formula I - both as pure enantiomers or pure diastereomers or as a mixture thereof - are preferred, in which the substituents have the following meaning:
- Y is nitrogen or CR 9 ; Z nitrogen or CR 10 ;
- R 2 C 1 -C 4 alkyl, C 2 -C 4 alkenyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, mercapto;
- CR 9 or CR 10 forms together with CR 9 or CR 10 a 5- or 6-membered alkylene or alkenylene ring, which can be substituted by one or two C 1 -C 4 alkyl groups, and in each case one or more methylene groups by oxygen, sulfur , -NH or -N (-CC 4 alkyl), can be replaced;
- R 3 and R 4 (which may be the same or different):
- Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group, an oxygen or sulfur atom or an S0 2 -, NH or N-alkyl group;
- R 5 is hydrogen, -CC 8 -alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 -alkynyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, mercapto, carboxy, amino, cyano, C -alkoxy, C 4 alkylthio, C ⁇ -C4-haloalkoxy, C ⁇ -C 4 alkylcarbonyl, C ⁇ -C 4 alkoxycarbonyl, NH (C 1 -C 4 alkyl), N (C ⁇ -C 4 alkyl) 2 , C 3 -C 8 cycloalkyl, heteroaryloxy or heteroaryl, five- or six-membered, containing one to three nitrogen atoms and / or a sulfur or oxygen atom,
- Phenoxy or phenyl where the aryl radicals mentioned can themselves be mono- to trisubstituted by halogen, Hydroxy, mercapto, cyano, -CC 4 alkyl, -C-C. 4 haloalkyl, C ⁇ -C alkoxy, C ⁇ -C4-haloalkoxy, C ⁇ -C 4 alkylthio, NH or N (C ⁇ -C4 alkyl) 2 (C -C 4 alkyl!);
- Phenyl or naphthyl which can each be mono- to trisubstituted by: halogen, cyano, hydroxy, amino, C 1 -C 4 alkyl, C -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 -Halogen- alkoxy, phenoxy, -CC 4 alkylthio, NH (C 1 -C 4 alkyl), N (-C 4 -alkyl) 2 , dioxomethylene or dioxoethylene;
- a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom which can carry one to four halogen atoms and / or one or two of the following radicals: C 1 -C 4 alkyl, C ⁇ -C- haloalkyl, C ⁇ -C 4 -alkoxy, C 4 haloalkoxy,
- C 3 -C 8 cycloalkyl where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, mercapto, C 1 -C 4 alkyl, CC 4 alkenyl, C 2 -C 4 alkynyl, C ⁇ - C 4 alkoxy, C 1 -C 4 alkylthio, C ⁇ -C 4 haloalkoxy;
- R 9 and R 10 (which may be the same as different):
- CR 9 or CR 10 is linked to CR 2 as stated under R 2 to form a 5- or 6-membered ring;
- Y is nitrogen or CR 9 ;
- R 2 C 1 -C 4 alkyl, trifluoromethyl, hydrogen, fluorine, -CC alkoxy, trifluoromethoxy, C 1 -C 4 alkylthio;
- CR 9 or CR 10 forms a 5- or 6-membered alkylene or alkenylene ring which can be substituted by one or two C 1 -C 4 alkyl groups, and in each case one or more methylene groups by oxygen or sulfur can be replaced;
- R 3 and R 4 (which may be the same or different):
- Phenyl or naphthyl which may be substituted by one or more of the following radicals: halogen, cyano, C alkyl, trifluoromethyl, C ⁇ -C 4 alkoxy, trifluoromethoxy, C 1 -C 4 alkylthio, or phenyl which is - Can be trisubstituted by halogen, -CC 4 alkyl, trifluoromethyl, C ⁇ -C 4 alkoxy or -CC alkylthio; or
- Phenyl or naphthyl which are ortho-linked via a direct bond, a methylene, ethylene or ethenylene group;
- R 5 is hydrogen, C 1 -C 8 -alkyl, C 3 -C 8 -alkenyl or C 3 -C 8 -alkynyl, where these radicals can each be mono- to trisubstituted by: halogen, hydroxy, mercapto, carboxy, cyano, amino, C ⁇ -C 4 alkoxy, C 1 -C 4 alkylthio, C ⁇ -C 4 alkoxycarbonyl, NH (C 1 -C 4 alkyl), N (C ⁇ -C4 alkyl) 2, C 3 -C 8- cycloalkyl, heteroaryloxy or heteroaryl, five- or six-membered, containing one to three nitrogen atoms and / or a sulfur or oxygen atom, phenoxy or phenyl, where the aryl radicals mentioned can in turn be mono- to trisubstituted by Halogen, cyano, hydroxy, C ⁇ -C 4 -alkyl, C ⁇ -C 4 -hal
- Phenyl or naphthyl which in each case may be substituted one to three times by: halogen, C ⁇ -C4 alkyl, trifluoromethyl, C ⁇ -C alkoxy, C ⁇ -C 4 -haloalkoxy, phenoxy, C ⁇ -C4-alkylthio, dioxomethylene or Dioxoethylene;
- a five- or six-membered heteroaromatic containing one to three nitrogen atoms and / or a sulfur or oxygen atom which can carry one to four halogen atoms and / or one or two of the following radicals: -CC alkyl, trifluoromethyl, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, phenyl, phenoxy, where the phenyl radicals in turn can carry one to five halogen atoms and / or one to three of the following radicals: C 1 -C 4 alkyl, C 1 -C 4 - Alkoxy or C ⁇ -C 4 alkylthio;
- R 9 and R 10 (which may be the same as different):
- CR 9 or CR 10 is linked to CR 2 as stated under R 2 to form a 5- or 6-membered ring;
- the compounds of the present invention offer new therapeutic potential for the treatment of hypertension, pulmonary hypertension, myocardial infarction, angina pectoris, arrhythmia acute / chronic kidney failure, chronic heart failure, renal failure, cerebral vasospasm, cerebral ischemia, subarachnoid hemorrhage, migraine, asthma, endherosis - toxic shock, endotoxin-induced organ failure, intravascular coagulation, restenosis after angioplasty and by-pass surgery, benign prostate hyperplasia, ischemic and intoxication-related kidney failure or hypertension, metastasis and growth of mesenchymal tumors such as prostate cancer, contrast agents induced kidney failure, pancreatitis, gastrointestinal ulcers.
- the invention further relates to combinations of endothelin receptor antagonists of the formula I and inhibitors of the renin-angiotensin system.
- Inhibitors of the renin-angiotensin system are renin inhibitors, angiotensin II antagonists and angiotensin converting enzyme (ACE) inhibitors.
- ACE angiotensin converting enzyme
- the invention further relates to combinations of endothelin receptor antagonists of the formula I and calcium antagonists such as verapamil.
- the invention further relates to combinations of endothelin receptor antagonists of the formula I and beta-blockers.
- the invention further relates to combinations of endothelin receptor antagonists of the formula I and diuretics.
- the invention further relates to combinations of endothelin receptor antagonists of the formula I and substances which block the action of VEGF (vascular endothelial growth factor).
- VEGF vascular endothelial growth factor
- substances which block the action of VEGF are, for example, antibodies directed against VEGF or specific binding proteins or also low-molecular substances which can specifically inhibit VEGF release or receptor binding.
- the combinations mentioned above can be administered simultaneously or sequentially in time. They can be used both in a single pharmaceutical formulation or in separate formulations.
- the form of application can also be different, for example the endo thelin receptor antagonists are administered orally and VEGF inhibitors are administered parenterally.
- the ET A or ET R receptor-expressing CHO cells were in DMEM NUT MIX F 12 medium (Gibco, No. 21331-020) with 10% fetal calf serum (PAA Laboratories GmbH, Linz, No. A15-022) , 1 mm
- Glutamine (Gibco No. 25030-024), 100 U / ml penicillin and 100 ⁇ g / ml streptomycin (Gibco, Sigma No. P-0781) increased. After 48 hours, the cells were washed with PBS and incubated with 0.05% trypsin-containing PBS for 5 minutes at 37 ° C. The mixture was then neutralized with medium and the cells were collected by centrifugation at 300 x g.
- the cells were adjusted to a concentration of 10 8 cells / ml buffer (50 mM Tris-HCl buffer, pH 7.4) and then disintegrated by ultrasound Branson Sonifier 250, 40-70 seconds / constant / output 20).
- the membranes were incubated in a 50 ⁇ g concentration in incubation buffer (50 mM Tris-HCl, pH 7.4 with 5 mM MnCl 2 , 40 mg / ml bacitracin and 0.2% BSA) Protein per test batch suspended and incubated at 25 ° C with 25 pM [125J] -ET ⁇ (ET A receptor test) or 25 pM [125J] -ET 3 (ET B receptor test) in the presence and absence of test substance. The non-specific binding was determined with 10 " 7 M ETi.
- test animals were given the test compounds i.v. 30 min before the ETI administration. injected (1 ml / kg). To determine the ET antagonistic properties, the blood pressure changes in the test animals were compared with those in the control animals.
- the animals are anesthetized with urethane and the carotid artery (for measuring blood pressure) and the jugular vein (application of big endothelin / endothelin 1) are catheterized.
- big endothelin (20 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) or ETI (0.3 ⁇ g / kg, Appl. Vol. 0.5 ml / kg) is given intravenously. Blood pressure and heart rate are continuously recorded over 30 minutes. The significant and long-lasting changes in blood pressure are calculated as the area under the curve (AUC).
- AUC area under the curve
- the AUC of the substance-treated animals is compared with the AUC of the control animals.
- the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally). It can also be applied with vapors or sprays through the nasopharynx.
- the dosage depends on the age, condition and weight of the patient and on the type of application.
- the daily dose of active ingredient is between approximately 0.5 and 100 mg / kg body weight when administered orally and between approximately 0.1 and 30 mg / kg body weight when administered parenterally.
- the new compounds can be used in the customary pharmaceutical application forms in solid or liquid form, for example as tablets, film-coated tablets, capsules, powders, granules, coated tablets, Suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
- the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al. : Pharmaceutical Technology, Thieme-Verlag, Stuttgart, 1991).
- the administration forms obtained in this way normally contain the active ingredient in an amount of 0.1 to 90% by weight.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des dérivés d'acide carboxylique de formule (I) dans laquelle les substituants ont la signification mentionnée dans la description, leur préparation et leur utilisation comme antagonistes du récepteur de l'endothéline.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996152763 DE19652763A1 (de) | 1996-12-18 | 1996-12-18 | Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
DE19652763 | 1996-12-18 | ||
DE19700884 | 1997-01-13 | ||
DE1997100884 DE19700884A1 (de) | 1997-01-13 | 1997-01-13 | Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
PCT/EP1997/006778 WO1998027070A1 (fr) | 1996-12-18 | 1997-12-04 | Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endotheline |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0946524A1 true EP0946524A1 (fr) | 1999-10-06 |
Family
ID=26032394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97952876A Withdrawn EP0946524A1 (fr) | 1996-12-18 | 1997-12-04 | Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endotheline |
Country Status (21)
Country | Link |
---|---|
US (1) | US6448248B1 (fr) |
EP (1) | EP0946524A1 (fr) |
JP (1) | JP2001506243A (fr) |
KR (1) | KR20000057642A (fr) |
CN (1) | CN1247533A (fr) |
AR (1) | AR010359A1 (fr) |
AU (1) | AU740351B2 (fr) |
BG (1) | BG103502A (fr) |
BR (1) | BR9714047A (fr) |
CA (1) | CA2275256A1 (fr) |
CO (1) | CO4930270A1 (fr) |
HR (1) | HRP970686A2 (fr) |
HU (1) | HUP0000553A3 (fr) |
ID (1) | ID26234A (fr) |
IL (1) | IL130251A0 (fr) |
NO (1) | NO313519B1 (fr) |
NZ (1) | NZ336157A (fr) |
PL (1) | PL334014A1 (fr) |
SK (1) | SK77799A3 (fr) |
TR (1) | TR199901416T2 (fr) |
WO (1) | WO1998027070A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1014989B1 (fr) * | 1997-09-26 | 2004-01-14 | Abbott GmbH & Co. KG | Antagoniste d'endotheline et systeme renine-angiotensine inhibiteur presentes sous forme de preparation pharmaceutique |
DE19743143A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
ES2238770T5 (es) * | 1997-10-17 | 2012-01-17 | Ark Therapeutics Limited | Utilización de inhibidores del sistema renina-angiotensina para el tratamiento de la hipoxia o de la disminución de la función metabólica. |
DE19806438A1 (de) * | 1998-02-17 | 1999-08-19 | Basf Ag | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung |
DE19858779A1 (de) * | 1998-12-18 | 2000-06-21 | Basf Ag | Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
DE19924892A1 (de) * | 1999-06-01 | 2000-12-07 | Basf Ag | Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
WO2001024827A2 (fr) * | 1999-10-06 | 2001-04-12 | Basf Aktiengesellschaft | Inhibiteurs de voie de signalisation de l'endotheline et antagonistes de recepteurs de l'integrine pour traitement combine |
FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
WO2003006041A1 (fr) * | 2001-07-12 | 2003-01-23 | Takeda Chemical Industries, Ltd. | Agents prophylactiques/therapeutiques contre les tumeurs malignes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2671551B1 (fr) * | 1991-01-15 | 1993-03-12 | Adir | Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19614534A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19614542A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
DE19614533A1 (de) | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
-
1997
- 1997-12-04 BR BR9714047-3A patent/BR9714047A/pt not_active IP Right Cessation
- 1997-12-04 IL IL13025197A patent/IL130251A0/xx unknown
- 1997-12-04 EP EP97952876A patent/EP0946524A1/fr not_active Withdrawn
- 1997-12-04 SK SK777-99A patent/SK77799A3/sk unknown
- 1997-12-04 CA CA002275256A patent/CA2275256A1/fr not_active Abandoned
- 1997-12-04 TR TR1999/01416T patent/TR199901416T2/xx unknown
- 1997-12-04 CN CN97181869A patent/CN1247533A/zh active Pending
- 1997-12-04 HU HU0000553A patent/HUP0000553A3/hu unknown
- 1997-12-04 AU AU56594/98A patent/AU740351B2/en not_active Ceased
- 1997-12-04 NZ NZ336157A patent/NZ336157A/xx unknown
- 1997-12-04 US US09/319,876 patent/US6448248B1/en not_active Expired - Fee Related
- 1997-12-04 ID IDW990558A patent/ID26234A/id unknown
- 1997-12-04 PL PL97334014A patent/PL334014A1/xx unknown
- 1997-12-04 KR KR1019990705445A patent/KR20000057642A/ko not_active Application Discontinuation
- 1997-12-04 WO PCT/EP1997/006778 patent/WO1998027070A1/fr not_active Application Discontinuation
- 1997-12-04 JP JP52724798A patent/JP2001506243A/ja active Pending
- 1997-12-16 HR HR19700884.4A patent/HRP970686A2/hr not_active Application Discontinuation
- 1997-12-16 AR ARP970105907A patent/AR010359A1/es not_active Application Discontinuation
- 1997-12-17 CO CO97073662A patent/CO4930270A1/es unknown
-
1999
- 1999-06-17 NO NO19992976A patent/NO313519B1/no not_active IP Right Cessation
- 1999-06-18 BG BG103502A patent/BG103502A/xx unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9827070A1 * |
Also Published As
Publication number | Publication date |
---|---|
BR9714047A (pt) | 2000-05-09 |
US6448248B1 (en) | 2002-09-10 |
HUP0000553A1 (hu) | 2001-04-28 |
ID26234A (id) | 2000-12-07 |
NO313519B1 (no) | 2002-10-14 |
KR20000057642A (ko) | 2000-09-25 |
CA2275256A1 (fr) | 1998-06-25 |
TR199901416T2 (xx) | 1999-08-23 |
AU5659498A (en) | 1998-07-15 |
HRP970686A2 (en) | 1998-10-31 |
AR010359A1 (es) | 2000-06-07 |
NZ336157A (en) | 2000-10-27 |
SK77799A3 (en) | 2000-02-14 |
CN1247533A (zh) | 2000-03-15 |
CO4930270A1 (es) | 2000-06-27 |
HUP0000553A3 (en) | 2001-08-28 |
JP2001506243A (ja) | 2001-05-15 |
IL130251A0 (en) | 2000-06-01 |
NO992976D0 (no) | 1999-06-17 |
PL334014A1 (en) | 2000-01-31 |
AU740351B2 (en) | 2001-11-01 |
NO992976L (no) | 1999-06-17 |
WO1998027070A1 (fr) | 1998-06-25 |
BG103502A (en) | 2000-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996011914A1 (fr) | Nouveaux derives d'acide carboxylique, leur preparation et leur utilisation | |
DE19636046A1 (de) | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten | |
EP0874829A1 (fr) | Derives d'acides amines, leur preparation et leur utilisation comme antagonistes de l'endotheline | |
EP0892788A1 (fr) | Nouveaux derives d'acide carboxylique, leur preparation et leur utilisation | |
WO1997038980A1 (fr) | Nouveaux derives d'acides carboxyliques, leur preparation et leur utilisation | |
EP0946524A1 (fr) | Derives d'acide carboxylique heterocycliques, leur preparation et leur utilisation comme antagonistes du recepteur de l'endotheline | |
WO1999023078A2 (fr) | Nouveaux derives d'acide carboxylique, portant des chaines laterales amidees; leur mode de production et leur utilisation en tant qu'antagonistes recepteurs d'endotheline | |
WO1998058916A1 (fr) | NOUVEAUX DERIVES D'ACIDE β-AMINO ET β-AZIDO CARBOXYLIQUE, LEUR PREPARATION ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE | |
EP1009741A1 (fr) | Nouveaux derives d'acide carboxylique, leur production et leur utilisation comme antagonistes mixtes des recepteurs d'endotheline et a? et et b? | |
EP1037883A1 (fr) | NOUVEAUX DERIVES D'ACIDE $g(a)-HYDROXYCARBOXYLIQUE HETEROCYCLIQUEMENT SUBSTITUES, LEUR PRODUCTION ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE | |
DE19806438A1 (de) | Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung | |
EP1140867A1 (fr) | Nouveaux derives d'acides beta-amido- et beta-sulfonamidocarboxyliques, leur production et leur utilisation comme antagonistes des recepteurs d'endotheline | |
WO2001005771A1 (fr) | Nouveaux derives d'acide carbonique avec cycle pyrimidine 5,6-substitue, fabrication de ces derives et utilisation en tant qu'antagonistes recepteurs d'endotheline | |
DE19809144A1 (de) | Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten | |
WO2000073276A2 (fr) | Nouveaux derives d'acide carboxylique comprenant des heterocycles d'azote substitues par aryle, leur preparation et leur utilisation comme antagonistes du recepteur d'entholine | |
DE19700884A1 (de) | Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten | |
DE19738578A1 (de) | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten | |
DE19652763A1 (de) | Heterozyklische Carbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten | |
WO2000009489A1 (fr) | Nouveaux derives de l'acide carbonique porteurs de chaines laterales cetone, leur fabrication et leur utilisation comme antagonistes des recepteurs de l'endotheline | |
DE19811915A1 (de) | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten | |
EP1286973A2 (fr) | Nouveaux carbamates et carbamides, fabrication de ces composes et utilisation en tant qu'antagonistes de recepteurs d'endotheline | |
DE19752904A1 (de) | Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten | |
WO2002064573A1 (fr) | Nouveaux derives d'acide carboxylique contenant des triazines a substitution alkyle, leur production et leur utilisation en tant qu'antagonistes du recepteur d'endotheline | |
DE10004052A1 (de) | Neue Carbonsäurederivate mit alkylsubstituierten Triazinen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten | |
DE19809376A1 (de) | Neue Carbonsäurederivate, die Amidseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990529 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: RO PAYMENT 19990529;SI PAYMENT 19990529 |
|
17Q | First examination report despatched |
Effective date: 20021028 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ABBOTT GMBH & CO. KG |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040701 |